Related by context. All words. (Click for frequent words.) 88 Serdaxin ® 82 clinical trials Archexin ® 76 Zoraxel TM 68 clinical trials Archexin 66 Elagolix 66 PNP inhibitor 65 sodium glucose cotransporter 65 FUSILEV ® 64 selective kinase inhibitor 64 XL# anticancer compounds 64 novel histone deacetylase 64 generation Hsp# inhibitor 63 FOLFOX6 chemotherapy regimen 63 oral prodrug 63 developing Bicifadine serotonin 63 proteasome inhibitors 63 IMPDH inhibitor 63 selective orally bioavailable 63 Archexin 63 proteasome inhibitor 63 dasatinib Sprycel ® 63 Serdaxin 63 imatinib Gleevec ® 63 Exelixis compounds 63 Solazed TM 62 2 methoxyestradiol 62 AAG geldanamycin analog 62 non thiazolidinedione TZD 62 oral nucleoside analogue 62 non nucleoside inhibitor 62 dextromethorphan quinidine 62 Tezampanel 62 mGluR5 negative 62 TAFA# 62 metaglidasen 62 histone deacetylase HDAC inhibitor 61 PEGylated Fab fragment 61 5 FU leucovorin 61 liposomal formulation 61 Epothilone D 61 LymphoStat B TM 61 oral proteasome inhibitor 61 cetuximab Erbitux R 61 virus HCV protease inhibitor 61 selective androgen receptor modulator 61 dasatinib Sprycel 61 product candidate Lpathomab 61 VEGFR2 inhibitor 61 receptor tyrosine kinase inhibitor 61 orally administered inhibitor 61 IMiDs ® 61 pan histone deacetylase 61 Cyclooxygenase Inhibiting Nitric Oxide 61 Perifosine 61 Omacetaxine 61 evaluating tivozanib 61 generation purine nucleoside 61 Vicriviroc 61 HSP# inhibitor 61 generation proteasome inhibitor 61 Phase IIb Trial 61 NU# direct 61 ocular formulation 61 radiation sensitizer 61 Aflibercept 60 erlotinib Tarceva ® 60 targeted radiotherapeutic 60 Panzem NCD 60 Panzem R 60 BLyS specific 60 multi kinase inhibitor 60 Maribavir 60 candidate deforolimus 60 sorafenib Nexavar 60 refractory chronic lymphocytic 60 highly selective inhibitor 60 nilotinib Tasigna ® 60 novel nucleoside analog 60 Thiarabine 60 IMiDs R 60 Phase #b/#a clinical 60 PI3K/Akt pathway inhibitor 60 Personalized Immunotherapy 60 Romidepsin 60 docetaxel Taxotere R 60 orally inhaled migraine 60 oxazolidinone 60 HGS# 60 Meets Primary Endpoint 60 TOCOSOL Camptothecin 60 modified glutathione analog 60 TKB# 60 Pimavanserin 60 NYSE Amex RNN 60 HGS ETR2 60 Completes Patient Enrollment 59 generation PNP inhibitor 59 novel immunomodulatory 59 selective immunoproteasome inhibitor 59 formerly LymphoStat B 59 delivery polymer matrix 59 sunitinib Sutent ® 59 Xeloda ® 59 PDE4 inhibitor 59 Talabostat 59 drug pipeline TAFA# 59 Ophena TM 59 allosteric modulator NAM 59 TELINTRA 59 Albuferon TM 59 triggers apoptosis programmed 59 novel topoisomerase 59 Annamycin 59 oncolytic virus therapies 59 R roscovitine CDK cyclin 59 R bortezomib 59 Hsp# Inhibitor 59 oral picoplatin 59 class anticancer quinolone 59 lintuzumab SGN 59 BiovaxID TM 59 signal transduction inhibitor 59 Myocet 59 demonstrated antitumor activity 59 Panzem R NCD 59 diabetic neuropathic pain 59 MKC# MT 59 Quinamed 59 Phase 2b Clinical Trial 59 KRN# 59 Initiates Phase II 59 Bezielle 59 vascular disrupting agents 59 antiangiogenesis therapies 59 HCV polymerase inhibitors 59 Crofelemer budesonide foam 59 Naproxcinod 59 XP# XP# 59 CYT# potent vascular disrupting 59 Tyrima 59 includes TOLAMBA TM 59 IAP inhibitors 59 hypoxia activated prodrug 59 Selzentry Celsentri 59 M# rationally 58 Voreloxin 58 Carfilzomib 58 Luramist TM 58 Xanafide 58 Gel repository corticotropin injection 58 IMA# 58 First Patient Dosed 58 Daclizumab 58 humanised monoclonal antibody 58 bosutinib 58 docetaxel Taxotere ® 58 ALN PCS 58 BYETTA ® 58 Cloretazine ® 58 XL# XL# XL# XL# 58 Initiates Phase III 58 evaluating satraplatin 58 R#/MEM # 58 PRN FDA Approves 58 rxRNA 58 signal detection CTSD 58 NS5B polymerase 58 Locteron combines 58 biomodulator 58 TM Aganocide 58 pralatrexate injection folate analogue 58 Phase 2a Clinical Trial 58 TO AVOID PREGNANCY WHILE 58 evaluating Xcytrin 58 TBC# 58 Presents Positive 58 SNRI 58 Darusentan 58 candidate CRLX# 58 Initiates Enrollment 58 Pazopanib 58 Fludara ® 58 OMNARIS HFA 58 candidates Azedra TM 58 Pruvel TM 58 SinuNase TM 58 nucleoside analog 58 Presents Preclinical Data 58 AEGR 58 Randomized Phase 58 Glufosfamide 58 adrenal steroid hormones 58 Receives Orphan Drug Designation 58 Dapagliflozin 58 LymphoStat B belimumab 58 Pivotal Phase III 58 Phase 2b clinical trials 58 tumor activated prodrug 58 aldehyde dehydrogenase ALDH2 deficiency 58 forodesine 58 Phase IIb Clinical Trial 58 plus prednisone prednisolone 58 Drug Candidate 58 oral isoform selective HDAC 58 BCG refractory carcinoma 58 Imprime PGG ® 58 Cannabinor 58 multitargeted 58 Azedra TM 58 TRIOLEX HE# APOPTONE HE# 58 ADP receptor antagonist 57 FOLOTYN ® 57 Safinamide 57 CCR9 antagonist 57 FEMALES SHOULD BE ADVISED 57 ATRA IV 57 evaluating picoplatin 57 vaccines oncolytic virus 57 ALN TTR 57 Initiate Phase 57 Medoxomil 57 investigational humanized monoclonal antibody 57 Elesclomol 57 HGS ETR1 57 rusalatide acetate 57 PEG irinotecan 57 Pertuzumab 57 sunitinib malate 57 Initiates Phase 57 sitagliptin Januvia 57 TNF Tumor Necrosis Factor 57 CB2 selective receptor agonist 57 tumor vascular disrupting 57 Zenvia ™ 57 CCX# 57 Deforolimus 57 lexidronam injection 57 Phase 2b Trial 57 KSP inhibitor 57 neuropathic pain metabolic diseases 57 mGluR2 positive 57 cetuximab Erbitux ® 57 Nexavar ® 57 gemcitabine Gemzar 57 Interferon alpha 57 bortezomib Velcade R 57 Ambrisentan 57 Synavive 57 Tasimelteon 57 Dyloject TM 57 rALLy clinical trial 57 GMX# 57 Nitazoxanide 57 allosteric modulator PAM 57 PHX# 57 mapatumumab 57 Combination REOLYSIN R 57 IL# PE#QQR 57 IMC A# 57 OvaRex ® MAb 57 investigational monoclonal antibody 57 dependent kinase inhibitor 57 agonistic human 57 Vidaza R 57 pertuzumab 57 Milnacipran 57 Study Evaluating 57 Serostim ® 57 Epothilones 57 Novel Oral 57 RGB # 57 TLR9 agonist 57 pegylated interferons 57 JAK1 57 BEMA Buprenorphine 57 Empatic ™ 57 Amigal TM 57 Seliciclib 57 OMP #R# 57 selective inverse agonist 57 hormone refractory metastatic prostate 57 candidate AQ4N 57 lenalidomide Revlimid R 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 MAGE A3 ASCI 57 trastuzumab Herceptin R 57 ® bortezomib 57 ospemifene 57 ZEVALIN ® 57 Preclinical studies suggest 57 novel VDA molecule 57 anti amnesic 57 PRT# 57 MEK Inhibitor 57 tanespimycin 56 Mg Usa 56 II Clinical Trial 56 Clinical Trial Results 56 PROSTASCINT R 56 Clofarabine 56 Telik logo TELINTRA 56 Camptosar ® 56 CYC# 56 Completes Enrollment 56 Previously Treated 56 pomalidomide 56 ® lenalidomide 56 selective androgen receptor modulators 56 including eniluracil ADH 56 ENMD # 56 alvespimycin 56 ALN HPN 56 HQK 56 MT# MEDI 56 adenosine injection 56 Angiocept 56 elotuzumab 56 TOCOSOL Paclitaxel 56 protein kinase inhibitor 56 BZL# 56 Silodosin 56 Paraplatin ® 56 Pruvel ™ 56 PEGylated irinotecan 56 Xcytrin R 56 TRAIL receptor antibodies 56 advanced metastatic renal 56 Presents Preclinical 56 Demonstrates Significant 56 PDE# 56 Amgen Neulasta R 56 phase IIb III 56 compound INCB# 56 peptidic compound 56 Initiates Clinical Trial 56 Aurora Kinase 56 MT#/MEDI-# 56 Dendreon investigational 56 YONDELIS 56 Vaccine Adjuvant 56 GVAX ® 56 adecatumumab MT# 56 sorafenib tablets 56 TPI ASM8 56 panitumumab Vectibix 56 relapsed multiple myeloma 56 DU #b 56 Dual Opioid 56 bevacizumab Avastin ® 56 Laquinimod 56 oral dihydropyrimidine dehydrogenase DPD 56 CINQUIL 56 monoclonal antibody IgG1 Mab 56 antibody MAb 56 cell carcinoma RCC 56 sapacitabine CYC# 56 Pivotal Phase 56 Alocrest 56 targeted antifolate 56 Novolimus 56 non nucleoside HCV 56 pan HDAC inhibitor 56 mertansine 56 RANK Ligand inhibitor 56 tezampanel 56 targeting CD# 56 indolent follicular non 56 Begins Dosing 56 Iloperidone 56 IMiDs 56 Zemiva TM 56 LibiGel ® 56 Preclinical Data 56 essential thrombocythemia ET 56 alfa 2a 56 bevacizumab Avastin R 56 JAK2 inhibitor 56 Bucindolol 56 interferon alfacon 1 55 systemic anaplastic large 55 anticoagulant reversing agent 55 Akt inhibitor 55 HGS ETR1 mapatumumab 55 Genentech Rituxan 55 IAP inhibitor 55 cannabinor 55 Vertex telaprevir 55 novel synthetic PEGylated 55 Sphingomab TM 55 Exherin 55 candidate bevirimat PA 55 Patient Enrollment 55 please visit http:/www.vandapharma.com 55 Effexor venlafaxine 55 Trial Evaluating 55 metastatic castration resistant 55 BENLYSTA TM 55 5 fluorouracil leucovorin 55 Ustekinumab 55 sorafenib Nexavar ® 55 Rebif ® 55 Phase Ib clinical trials 55 induced mucositis 55 Perifosine KRX 55 OvaRex R 55 topical anti infective 55 Investigational Compound 55 Atripla combines 55 Oral Fingolimod 55 mGluR5 antagonists 55 CORT # 55 interferon gamma 1b 55 ACAPODENE TM 55 Frova ® 55 BiTE R 55 Investigational Oral 55 approved incretin mimetic 55 paclitaxel Taxol 55 AEG# 55 RhuDex ® 55 Vitrasert R 55 Ixempra 55 ganetespib 55 5 FU capecitabine 55 novel oral anticoagulant 55 albiglutide 55 MOVIPREP R 55 R sorafenib tablets 55 teriflunomide 55 Temsirolimus 55 selective estrogen receptor 55 Antitumor Activity 55 products MKC# PP 55 Parnate 55 RhuDex TM 55 telomerase therapeutic 55 clinical trials dacetuzumab SGN 55 Janus Kinase 55 AN# topical anti 55 SPRYCEL ® 55 PEGylated interferon beta 1a 55 Xeloda capecitabine 55 Vidaza azacitidine 55 Ostabolin C TM 55 arsenic trioxide injection 55 TURNING INSIGHTS INTO HOPE 55 MSCRAMM ® 55 motexafin gadolinium Injection 55 CCX# B 55 LY# [003] 55 entinostat 55 phase IIa clinical 55 cyclophosphamide doxorubicin vincristine 55 clinical trials SGN 55 IRX 2 55 corticotropin injection 55 tubulin inhibitor 55 SinuNase ™ 55 Diabetic Macular Edema 55 PANVAC VF 55 oral ridaforolimus 55 small molecule defensin 55 DPP4 inhibitor 54 direct thrombin inhibitors 54 AVONEX ® 54 Targretin 54 SAR# [004] 54 novel DACH platinum 54 Leukine ® 54 GABITRIL 54 Varespladib 54 Sporanox 54 CTAP# Capsules 54 Phase 2a Trial 54 FUSILEV enhances 54 Kinase Inhibitor 54 Hsp# inhibition 54 Epratuzumab 54 Sagar Lonial MD 54 Cancidas 54 oral rivaroxaban 54 ZOLINZA 54 R lenalidomide 54 anti atherothrombotic 54 Tarceva TM 54 Darinaparsin 54 recurrent metastatic ovarian cancer 54 Ridaforolimus 54 Telintra 54 Ozarelix 54 Bafetinib 54 registrational trial 54 paclitaxel Taxol ® 54 Phase 1b trial 54 Phase Ib study 54 Syncria 54 humanized interleukin 6 54 Anavex #-# 54 Topline Results 54 Doxil ® 54 thetreatment 54 candidates Augment ™ 54 toenail onychomycosis 54 sulodexide 54 GW# [003] 54 small molecule tyrosine 54 Announces Poster Presentations 54 Achieves Primary Endpoint 54 modulators SERMs 54 docetaxel Taxotere 54 SPIRIVA ® 54 vapreotide acetate 54 KNS # 54 HuMax EGFr 54 anti EGFR antibody 54 lintuzumab 54 TLR7 agonist 54 selective estrogen receptor modulator 54 MyVax R 54 Cutaneous T 54 Hormone Refractory Prostate Cancer 54 Cephalon Oncology 54 small molecule thrombopoietin 54 TNF alpha selectively neutralizing 54 Nanobody ® 54 induced macular edema 54 Factor VIIa 54 tumor xenograft models 54 topical antifungal product 54 Apoptone 54 BAY #-# 54 regorafenib 54 Inc. OTCBB LPTN 54 OMP #M# 54 omacetaxine mepesuccinate 54 YONDELIS R 54 D aspartate NMDA receptor 54 Peginterferon alfa 2b 54 Delta opioid receptor 54 peripheral sensory neuropathy 54 generation nucleoside analog 54 Pemetrexed 54 BRAF inhibitor 54 Combivir Kivexa 54 apoptosis inducer 54 DNA methyltransferase inhibitors 54 SUCCEED trial 54 developing ostarine selective 54 Ceflatonin R 54 Elotuzumab 54 Initiate Phase III 54 Initiates Clinical 54 Factor Receptor 54 defensin mimetic antibiotic 54 rilonacept Injection 54 Traficet EN 54 Fc fusion protein 54 TRACON Pharmaceuticals 54 TLK# 54 BENLYSTA ™ 54 HCD# [002] 54 Vfend 54 dermatology therapies 54 Brentuximab Vedotin SGN 54 includes AstraZeneca Accolate 54 leukotriene receptor antagonist 54 Pralatrexate 54 telomerase inhibitor drug 54 docetaxel chemotherapy 54 Tablets #mg [002] 54 CDK cyclin dependent 53 Tumour Vascular Disrupting Agent 53 Amrubicin 53 Investigational Treatment 53 Elvitegravir 53 refractory cutaneous T 53 Aplidin 53 humanized therapeutic 53 Marqibo TM 53 IMiDs ® compound 53 metastatic castrate resistant 53 Muraglitazar 53 antimetabolite 53 delivers fluocinolone acetonide FA 53 Romiplostim 53 Taxotere chemotherapy 53 long acting beta2 53 Ereska 53 novel orally bioavailable 53 negative allosteric modulator 53 ularitide 53 metastatic hormone refractory 53 mitoxantrone plus 53 Vidaza ® 53 cisplatin gemcitabine 53 oral chemotherapeutic agent 53 huC# DM4 53 Phase Ib II 53 Treanda 53 hyaluronidase enzyme 53 HuMax 53 TNFerade ™ 53 PEG SN# 53 CD# CEA 53 plus prednisone 53 oral immunomodulatory 53 Panitumumab 53 inhibits dihydrofolate reductase 53 estrogen receptor antagonist 53 ixabepilone 53 amrubicin 53 vidofludimus 53 gemcitabine cisplatin 53 Granulocyte Colony Stimulating Factor 53 novel tubulin binding 53 neratinib 53 Fenofibrate 53 initiated Phase Ib 53 BN# [004] 53 levocetirizine 53 IMC #B 53 Bortezomib 53 Paliperidone Palmitate 53 CK # novel 53 Phase III Clinical Trials 53 DNA demethylating agent 53 Well Tolerated 53 vinca alkaloids 53 relapsed MM 53 Neulasta R 53 androgen receptor modulator 53 DOXIL 53 acetonide FA 53 CA4P 53 SinuNase 53 GVAX R 53 baminercept 53 Eraxis 53 xenograft models 53 Panzem ® 53 anidulafungin 53 class mGluR5 inhibitor 53 SUTENT ® 53 Campath alemtuzumab 53 Myelofibrosis 53 psoriasis rheumatoid arthritis 53 gefitinib Iressa 53 CINOD 53 DMAG 53 compound perifosine 53 Kristalose ® lactulose 53 Previously Untreated 53 PLK1 SNALP 53 anionic backbone 53 epigenetic therapies 53 generation DACH Platinum 52 enzastaurin 52 pharmacogenomic translational research 52 dexamethasone Decadron 52 OPAXIO TM 52 CRLX# 52 accumulate preferentially 52 refractory Hodgkin lymphoma 52 beta 1a 52 retaspimycin hydrochloride 52 gastrointestinal stromal 52 Adenoscan R 52 Through Glycoscience R 52 Rituxan rituximab 52 Telaprevir 52 Mycamine 52 Celgene Revlimid 52 Hycamtin ® 52 novel MetAP 2 52 HCl Tablets 52 corticosteroid dexamethasone 52 dacarbazine DTIC 52 anthracycline taxane 52 Fulvestrant 52 neuropathy sparing 52 resistant hormone refractory 52 Inc. NASDAQ ZLCS 52 TELINTRA R 52 Radiation Therapy SIRT 52 DCVax R 52 HuMax CD# 52 chemotherapy FOLFOX 52 axitinib 52 Receives Orphan Drug 52 Phase 1b clinical trials 52 Zarnestra 52 INCB# [001] 52 aripiprazole Abilify 52 Bayer HealthCare Onyx Pharmaceuticals 52 Tarvacin Anti Cancer 52 JAK2 Inhibitor 52 omega interferon 52 polycythemia vera essential thrombocythemia 52 ARIKACE ™ 52 Budesonide foam crofelemer 52 Tibotec Therapeutics division 52 Therapeutic Competitors Companies 52 Belinostat 52 Atiprimod 52 Celebrex celecoxib 52 Treatment Naïve 52 Advanced Renal Cell 52 HP Acthar Gel repository 52 INSPIRE Trial Phase III 52 www.ucb group.com 52 Civacir 52 protein kinase inhibitors 52 Phase IIb trials 52 #nd EORTC NCI 52 HuMax TAC 52 Pegasys peginterferon alfa 2a 52 Successfully Completes Phase 52 Tovaxin ® 52 Immunotherapeutic 52 compound PMX # 52 cathepsin K inhibitor 52 oral JAK1 52 bendamustine 52 oral deforolimus 52 tafamidis 52 injectable intravascular contrast 52 non porcine pancreatic 52 systemically administered 52 Icatibant 52 davunetide intranasal AL 52 alemtuzumab Campath 52 Solazed 52 Donating CINOD class 52 Pivotal Trial 52 development peramivir neuraminidase 52 Phase #/#a trial 52 Rigel R# 52 TG# [003] 52 Intravitreal 52 CYPHER R Sirolimus Eluting 52 bazedoxifene conjugated estrogens 52 platform HDL Mimetic 52 Evoltra ® 52 oral calcitonin licensed 52 Benlysta belimumab 52 tumors GIST 52 Cotara ® 52 NASDAQ ISTA 52 Omnitarg 52 HuMax CD4 52 Hedgehog Pathway Inhibitor 52 Trastuzumab DM1 52 Cethrin R 52 oral anti arrhythmic 52 PSN# [001] 52 Dexilant 52 developing ACAPODENE 52 AstraZeneca Symbicort 52 Gleevec imatinib mesylate 52 R Bortezomib 52 Tykerb lapatinib 52 ProSavin 52 histone methyltransferases HMTs 52 Anti Tumor 52 Dual Opioid TM 52 palonosetron hydrochloride Injection Dacogen 52 multicenter Phase III 52 alpha folate receptor 51 RAS MAPK pathway 51 adalimumab Humira 51 Sapacitabine 51 VELCADE melphalan 51 Phase 2a trial 51 PXD# 51 TRX1 51 Rexahn Pharmaceuticals Inc. 51 Sitagliptin 51 MCSP respectively 51 eniluracil 51 Anthracycline 51 compound ISA# 51 investigational antiplatelet 51 paroxetine Paxil 51 programs visit http:/www.bionovo.com 51 mGluR2 NAM 51 oral salmon calcitonin 51 Telavancin 51 Warfarin Coumadin 51 Alzhemed TM 51 incyclinide 51 Interferon Beta 51 Alinia 51 retinal vein occlusion induced 51 OMNARIS Nasal Spray 51 Sanofi Aventis Taxotere 51 clozapine Clozaril 51 Tocosol Paclitaxel 51 Allovectin 7 R 51 chemosensitizer 51 Refractory Hodgkin Lymphoma 51 nilotinib Tasigna 51 Metaphore 51 uric acid lowering 51 CD4 monoclonal antibody 51 Inc. Nasdaq IMGN 51 Epeius Biotechnologies Corporation 51 cytotoxics 51 PTK# 51 sarcoma melanoma 51 cediranib 51 Catalyst Biosciences 51 Benign Prostatic Hyperplasia 51 cetuximab Erbitux 51 Roche Chugai s 51 Protalex Inc. 51 LEUKINE 51 anti tumor necrosis 51 antithrombotics 51 deforolimus 51 ErbB2 positive 51 phase IIb trial 51 Pirfenidone 51 Phase 1b Clinical Trial 51 Combunox 51 etanercept Enbrel 51 pentadentate logo R 51 Cerimon 51 novel antimitotic agent 51 EXPAREL TM 51 Vivecon 51 gemcitabine Gemzar R 51 galiximab 51 Trofex TM 51 Ceflatonin 51 CIMZIA TM 51 Grb 2 51 Maleate 51 Neulasta ® 51 stent DES 51 Phase IIb clinical trials 51 XmAb# 51 small molecule activator 51 Syncria R 51 bone marrow reticulin deposition 51 generation Hsp# inhibitors 51 FOLFOX6 51 Gemin X 51 BioSante Pharmaceuticals NASDAQ BPAX 51 Celsion Corporation 51 elacytarabine 51 DXL# 51 CBLC# 51 Antiangiogenic 51 receptor inhibiting monoclonal 51 Phase III Pivotal 51 plus Copegus R 51 EndoTAG TM -1 51 dexanabinol 51 Aeolus Pharmaceuticals 51 Oral Calcitonin 50 Liprotamase 50 cognitive impairment associated 50 GlaxoSmithKline Lamictal 50 Allovectin 7 50 DOV Pharmaceutical Inc. 50 Celgene Thalomid 50 Nexavar sorafenib 50 OMRIX Biopharmaceuticals Inc. 50 Sudhir Agrawal D.Phil 50 rash pruritus nausea 50 talactoferrin 50 Arcalyst 50 HuLuc# 50 Granted Orphan Drug 50 Rindopepimut 50 molecularly targeted 50 irinotecan containing 50 Cancer Cachexia 50 luteinizing hormone releasing 50 R rilonacept Injection 50 NovaBay Pharmaceuticals 50 Xcellerated T Cells 50 CCR5 mAb 50 EFFEXOR XR 50 Proxinium TM 50 Intravitreal injections 50 substantially excreted 50 generation geldanamycin analog 50 Gastrointestinal Stromal Tumors 50 prasugrel CS 50 risperidone Risperdal 50 PF # [002] 50 5 HT2A serotonin 50 Intravenous CP 50 Ocrelizumab 50 phase Ib 50 Hematological Malignancies 50 Anticancer Compound 50 Advaxis Phase 50 BRIM2 50 Micromet proprietary BiTE 50 Abiraterone Acetate 50 cyclophosphamide methotrexate 50 ELACYT 50 adapalene 50 telcagepant 50 Ostarine ™ 50 Genz # 50 OXi# 50 SYN# 50 Azacitidine 50 LT NS# 50 Reports Preclinical Data 50 selective inhibition 50 OHR/AVR# 50 please visit www.abraxane.com 50 Pfizer Zoloft 50 Agile Therapeutics 50 GALNS 50 Actos pioglitazone 50 ORENCIA R 50 Prolongs Survival 50 Satraplatin 50 peripheral neuropathy aggravated 50 Regeneron Pharma 50 carboplatin paclitaxel 50 TTF Therapy 50 First Patient Enrolled 50 SUSTENNA TM 50 systemic Phase 1b 50 ZYBRESTAT fosbretabulin 50 carcinoma mCRC 50 Ep CAM 50 hematological cancers notably 50 Bevacizumab 50 potent antiproliferative 50 otelixizumab 50 NASDAQ IDRA 50 markets Testim ® 50 Licenses Novel 50 MetroGel R 50 Afferent Pharmaceuticals 50 INC# 50 RLY# 50 GRN# 50 Exherin TM 50 Advanced Melanoma 50 VEGF inhibitors 50 EZN 50 infliximab monotherapy 50 Risperdal risperidone 50 Kelly Luethje #-#-# 50 Pfizer Lyrica 50 Lupuzor 50 AS# amonafide L malate 50 UCB Keppra 50 Barry D. Quart 50 PRNewswire FirstCall Pharmacopeia 50 Diasome 50 Nasdaq IDIX 50 RISPERDAL ® 50 AVRX 50 Treatment Resistant 49 liposomal doxorubicin 49 Anchor Therapeutics 49 Tranzyme Pharma 49 Vandetanib 49 Aegis Therapeutics 49 pegylated liposomal doxorubicin 49 events thrombocytopenia neutropenia 49 BRAF mutant 49 Novartis Gleevec 49 Therapeutic Competitors companiesandmarkets.com adEgemonye 49 TSX YM AIM 49 trastuzumab DM1 49 therapeutic peptide 49 NASDAQ OGXI 49 MEDA AB publ 49 brentuximab vedotin SGN 49 ISTA Pharmaceuticals 49 Eli Lilly Prozac 49 Receives Milestone Payment 49 Akesis Pharmaceuticals 49 oral anticoagulant 49 EOquin TM phase 49 midstage clinical 49 KemPharm 49 RE SURGE 49 Zensana TM 49 Eribulin 49 estramustine 49 Degarelix 49 Avastin Herceptin 49 AstraZeneca Arimidex 49 Nasdaq VRTX 49 relapsed ovarian cancer 49 ImmunoGen Inc. 49 ZYBRESTAT 49 Lupus Nephritis